Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_assertion type Assertion NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_head.
- NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_assertion description "[Tyrosine kinase inhibitors directed against the epidermal growth factor receptor (EGFR) are the first molecular-targeted agents to be approved in the US and other countries for the treatment of advanced non-small-cell lung cancer after failure of chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_provenance.
- NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_assertion evidence source_evidence_literature NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_provenance.
- NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_assertion SIO_000772 16270096 NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_provenance.
- NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_assertion wasDerivedFrom befree-2016 NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_provenance.
- NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_assertion wasGeneratedBy ECO_0000203 NP521036.RAdpqdJ0Ac3j32q_moABPKqguW8HKdLutAemeeCCliBXo130_provenance.